HIF-1α (Hypoxia-Inducible Factor-1 alpha) stabilization therapy is a novel treatment approach that leverages the body's natural hypoxia response to protect neurons from degeneration. This therapy uses small molecules called prolyl hydroxylase inhibitors (PHIs) to stabilize HIF-1α, thereby activating a cascade of protective genes involved in energy metabolism, vascular function, and cellular stress responses[1][2].
Under normal oxygen conditions (normoxia), HIF-1α is continuously degraded by the proteasome. Prolyl hydroxylase domain enzymes (PHD1-3) use oxygen to hydroxylate HIF-1α, targeting it for von Hippel-Lindau (VHL) E3 ubiquitin ligase-mediated degradation[3].
PHIs inhibit PHD activity, preventing HIF-1α hydroxylation and degradation. This allows HIF-1α to translocate to the nucleus, dimerize with HIF-1β, and activate transcription of target genes[4].
The stabilization of HIF transcription factors leads to upregulation of:
In APP/PS1 mouse models of AD, HIF stabilization reduced amyloid-beta plaque burden, improved synaptic plasticity, and enhanced cognitive function[5][6]. The mechanism involves increased expression of amyloid-degrading enzymes (neprilysin, IDE) and improved cerebral blood flow[7].
In MPTP and 6-OHDA models of PD, HIF-1α stabilization protected dopaminergic neurons from cell death. Studies showed reduced neuroinflammation and improved motor function[8][9].
In SOD1-G93A ALS mouse models, HIF stabilization delayed disease onset and extended survival. The neuroprotective effects were mediated through improved mitochondrial function and reduced oxidative stress[10].
In R6/2 and YAC128 HD mouse models, HIF-1α stabilization via PHD inhibition reduced mutant huntingtin (mHTT) aggregation, improved mitochondrial function, and enhanced motor performance. Studies show HIF activation promotes autophagy of mHTT aggregates and protects striatal neurons[11][12].
While direct clinical trials in CBS/PSP are lacking, preclinical evidence suggests HIF stabilization may enhance cellular resilience in 4R-tauopathies. PHD inhibition reduced tau pathology in tau transgenic models and protected against oxidative stress in neuronal cultures derived from CBS/PSP patients[13][14].
| Drug | Status | Company |
|---|---|---|
| Roxadustat (FG-4592) | Approved (US, EU, Japan) | FibroGen/Astellas/AstraZeneca |
| Vadadustat (AKB-6548) | Approved (US) | Akebia Therapeutics |
| Daprodustat (GSK1278863) | Approved (Japan, US) | GlaxoSmithKline |
Currently, no large-scale clinical trials of PHIs for AD or PD are registered. However, several phase 1/2 trials are investigating:
Common adverse reactions include:
Serious adverse events include:
HIF stabilization represents a promising disease-modifying approach because it:
Semenza, G.L. (2012). HIF-1 and human disease: a highly complex relationship. Annual Review of Pathology. 2012. ↩︎
SchITO, J.M. & Melillo, G. (2010). Targeting hypoxia inducible factor-1 for cancer therapy. Frontiers in Oncology. 2010. ↩︎
Kaelin, W.G. & Ratcliffe, P.J. (2008). Oxygen sensing by metazoan HIF hydroxylases. Molecular Cell. 2008. ↩︎
Maxwell, P.H. & Eckardt, K.U. (2016). HIF prolyl hydroxylase inhibitors for anemia. Nature Reviews Nephrology. 2016. ↩︎
Li, L. et al. (2019). HIF-1α activation ameliorates Alzheimer's disease. Neurobiology of Aging. 2019. ↩︎
Liu, X. et al. (2020). Prolyl hydroxylase inhibition reduces amyloid pathology. Journal of Alzheimer's Disease. 2020. ↩︎
Cheng, Y. et al. (2021). HIF stabilization enhances cerebral blood flow in AD. Stroke. 2021. ↩︎
Xia, D. et al. (2017). HIF-1α protects against Parkinsonian neurotoxicity. Cell Death & Disease. 2017. ↩︎
Zhang, Z. et al. (2019). Roxadustat attenuates MPTP-induced PD models. Neuropharmacology. 2019. ↩︎
Liu, Y. et al. (2022). HIF prolyl hydroxylase inhibition in ALS models. Acta Neuropathologica Communications. 2022. ↩︎
Tardelli M, et al. (2020). HIF-1α activation ameliorates Huntington's disease pathology. Nature Communications. 2020. ↩︎
Giampetro C, et al. (2022). Prolyl hydroxylase inhibition reduces mHTT aggregation in HD models. Brain. 2022. ↩︎
Choi H, et al. (2021). HIF-1α stabilization reduces tau pathology in 4R-tauopathy models. Acta Neuropathologica. 2021. ↩︎
Rahman M, et al. (2023). Prolyl hydroxylase inhibition protects neurons against oxidative stress in CBS/PSP. Neurobiology of Disease. 2023. ↩︎